Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$103.13 +2.4%	$91.61	$81.97 ▼ $137.49	$179.51B	0.61	12.59 million shs	10.37 million shs
AMGN Amgen	$376.04 +1.2%	$351.28	$269.77 ▼ $391.29	$202.95B	0.41	2.16 million shs	2.49 million shs
GILD Gilead Sciences	$129.31 -1.2%	$129.55	$108.46 ▼ $157.29	$160.55B	0.32	7.12 million shs	5.53 million shs
PFE Pfizer	$24.53 -1.9%	$25.11	$23.11 ▼ $28.75	$139.86B	0.35	41.06 million shs	28.88 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	+2.40%	+10.75%	+13.14%	-18.02%
AMGN Amgen	0.00%	+2.66%	+6.58%	+9.14%	+21.61%
GILD Gilead Sciences	0.00%	-3.70%	+4.42%	-0.84%	+13.87%
PFE Pfizer	0.00%	-2.21%	+3.77%	-9.19%	-3.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$103.13 +2.4%	$91.61	$81.97 ▼ $137.49	$179.51B	0.61	12.59 million shs	10.37 million shs
AMGN Amgen	$376.04 +1.2%	$351.28	$269.77 ▼ $391.29	$202.95B	0.41	2.16 million shs	2.49 million shs
GILD Gilead Sciences	$129.31 -1.2%	$129.55	$108.46 ▼ $157.29	$160.55B	0.32	7.12 million shs	5.53 million shs
PFE Pfizer	$24.53 -1.9%	$25.11	$23.11 ▼ $28.75	$139.86B	0.35	41.06 million shs	28.88 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	+2.40%	+10.75%	+13.14%	-18.02%
AMGN Amgen	0.00%	+2.66%	+6.58%	+9.14%	+21.61%
GILD Gilead Sciences	0.00%	-3.70%	+4.42%	-0.84%	+13.87%
PFE Pfizer	0.00%	-2.21%	+3.77%	-9.19%	-3.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.92	Moderate Buy	$118.61	15.01% Upside
AMGN Amgen	2.43	Hold	$356.62	-5.17% Downside
GILD Gilead Sciences	2.86	Moderate Buy	$158.33	22.44% Upside
PFE Pfizer	2.19	Hold	$28.50	16.21% Upside

Current Analyst Ratings Breakdown

Latest AMGN, GILD, PFE, and ABT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	ABT Abbott Laboratories	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
7/21/2026	GILD Gilead Sciences	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$146.00 ➝ $127.00
7/17/2026	ABT Abbott Laboratories	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$108.00 ➝ $112.00
7/17/2026	ABT Abbott Laboratories	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$115.00 ➝ $118.00
7/17/2026	ABT Abbott Laboratories	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$110.00 ➝ $120.00
7/17/2026	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$109.00 ➝ $112.00
7/17/2026	ABT Abbott Laboratories	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
7/17/2026	ABT Abbott Laboratories	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$130.00
7/17/2026	ABT Abbott Laboratories	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$131.00 ➝ $134.00
7/15/2026	AMGN Amgen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
7/13/2026	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$400.00 ➝ $420.00

(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$44.33B	4.05	$7.00 per share	14.74	$30.35 per share	3.40
AMGN Amgen	$36.75B	5.52	$33.82 per share	11.12	$16.08 per share	23.39
GILD Gilead Sciences	$29.44B	5.45	$10.47 per share	12.35	$18.23 per share	7.09
PFE Pfizer	$62.58B	2.23	$4.40 per share	5.58	$15.26 per share	1.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$6.52B	$3.09	33.38	16.96	2.00	11.65%	17.65%	9.83%	N/A
AMGN Amgen	$7.71B	$14.37	26.17	15.76	3.80	20.96%	137.41%	13.28%	8/4/2026 (Estimated)
GILD Gilead Sciences	$8.51B	$7.34	17.62	13.29	N/A	30.99%	48.19%	18.28%	8/4/2026 (Confirmed)
PFE Pfizer	$7.77B	$1.31	18.72	8.61	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest AMGN, GILD, PFE, and ABT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GILD Gilead Sciences	-$7.2478	N/A	N/A	N/A	$7.39 billion	N/A
8/4/2026	Q2 2026	AMGN Amgen	$5.62	N/A	N/A	N/A	$9.43 billion	N/A
8/4/2026	Q2 2026	PFE Pfizer	$0.68	N/A	N/A	N/A	$14.42 billion	N/A
7/16/2026	Q2 2026	ABT Abbott Laboratories	$1.28	$1.31	+$0.03	$0.53	$12.52 billion	$12.51 billion
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.52	2.44%	+10.39%	81.55%	54 Years
AMGN Amgen	$10.08	2.68%	+8.27%	70.15%	14 Years
GILD Gilead Sciences	$3.28	2.54%	+3.04%	44.69%	10 Years
PFE Pfizer	$1.72	7.01%	-13.20%	131.30%	16 Years

Latest AMGN, GILD, PFE, and ABT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.01%	7/24/2026	7/24/2026	9/1/2026
6/12/2026	ABT Abbott Laboratories	quarterly	$0.63	2.82%	7/15/2026	7/15/2026	8/17/2026
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.64%	6/15/2026	6/15/2026	6/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.56	1.39	1.01
AMGN Amgen	5.65	1.26	1.01
GILD Gilead Sciences	0.89	1.97	1.77
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AMGN Amgen	0.85%
GILD Gilead Sciences	0.30%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	115,000	1.74 billion	1.73 billion	Optionable
AMGN Amgen	31,500	539.71 million	535.12 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

AMGN, GILD, PFE, and ABT Headlines

Recent News About These Companies

Pfizer’s Bold Pipeline Bets Aim to Revive PFE

July 25 at 11:11 AM | tipranks.com

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.

July 25 at 8:51 AM | finance.yahoo.com

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.

July 25 at 8:50 AM | fool.com

Pfizer's Dividend Yield Looks Almost Too Good. Here's Why Management Isn't Worried.

July 25 at 8:15 AM | fool.com

Healthcare of Ontario Pension Plan Trust Fund Trims Stock Holdings in Pfizer Inc. $PFE

July 25 at 6:08 AM | marketbeat.com

Hilltop Holdings Inc. Decreases Stock Position in Pfizer Inc. $PFE

July 25 at 5:52 AM | marketbeat.com

Sei Investments Co. Lowers Stock Holdings in Pfizer Inc. $PFE

July 25 at 5:19 AM | marketbeat.com

Lido Advisors LLC Sells 141,542 Shares of Pfizer Inc. $PFE

July 25 at 5:19 AM | marketbeat.com

Cumberland Partners Ltd Buys 61,285 Shares of Pfizer Inc. $PFE

July 25 at 4:24 AM | marketbeat.com

Pfizer Inc. $PFE Shares Acquired by Epoch Investment Partners Inc.

July 25 at 4:23 AM | marketbeat.com

Traders Buy High Volume of Pfizer Call Options (NYSE:PFE)

July 25 at 2:01 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Healthcare Services (HCSG)

July 24 at 6:37 PM | theglobeandmail.com

Pfizer (NYSE:PFE) Shares Down 1.9% - Here's What Happened

July 24 at 5:19 PM | marketbeat.com

Pfizer’s PF-08057418 Clears Phase 1 Safety Milestone, Offering a Quiet Boost to Pipeline Confidence

July 24 at 12:51 PM | tipranks.com

Pfizer Advances New Obesity Shot With Early Stage Trial of PF-08653945

July 24 at 12:51 PM | tipranks.com

Wills Financial Group LLC Increases Position in Pfizer Inc. $PFE

July 24 at 6:41 AM | marketbeat.com

Pfizer Inc. $PFE Shares Bought by Public Employees Retirement System of Ohio

July 24 at 6:34 AM | marketbeat.com

Cetera Investment Advisers Boosts Position in Pfizer Inc. $PFE

July 24 at 3:56 AM | marketbeat.com

BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring

July 23 at 7:33 PM | fool.com

Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer

July 23 at 5:31 PM | fool.com

Investors Purchase High Volume of Call Options on Pfizer (NYSE:PFE)

July 23 at 4:39 PM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AMGN, GILD, PFE, and ABT Company Descriptions

Abbott Laboratories NYSE:ABT

$103.13 +2.38 (+2.36%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$103.12 0.00 (0.00%)

As of 07/24/2026 07:16 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$376.04 +4.54 (+1.22%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$374.50 -1.54 (-0.41%)

As of 07/24/2026 07:34 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$129.31 -1.55 (-1.18%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$130.46 +1.15 (+0.89%)

As of 07/24/2026 07:34 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Pfizer NYSE:PFE

$24.52 -0.49 (-1.94%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$24.54 +0.01 (+0.04%)

As of 07/24/2026 07:33 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AMGN, GILD, PFE, and ABT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AMGN, GILD, PFE, and ABT Earnings

Compare Dividends

Latest AMGN, GILD, PFE, and ABT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AMGN, GILD, PFE, and ABT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AMGN, GILD, PFE, and ABT Company Descriptions

Abbott Laboratories NYSE:ABT

Amgen NASDAQ:AMGN

Gilead Sciences NASDAQ:GILD

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools